The Technical Analyst
Qualigen Therapeutics Inc [QLGN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Qualigen Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.85% $0.297
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.873 mill |
| EPS: | -2.46 |
| P/E: | -0.120 |
| Earnings Date: | May 14, 2024 |
| SharesOutstanding: | 6.31 mill |
| Avg Daily Volume: | 0.0673 mill |
| RATING 2024-04-25 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.120 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.120 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.177 (-159.57%) $-0.474 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.256 - 0.344 ( +/- 14.69%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-07-11 | Abdul-ahad Wajdi | Buy | 80 000 | Stock Option (Right to Buy) |
| 2022-07-11 | Lotz Christopher L. | Buy | 100 000 | Stock Option (Right to Buy) |
| 2022-07-11 | Lotz Christopher L. | Buy | 100 000 | Stock Option (Right to Buy) |
| 2022-07-11 | Arshad Tariq | Buy | 102 000 | Stock Option (Right to Buy) |
| 2022-07-11 | Ritter Ira E. | Buy | 40 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 89 transactions |
| Buy: 8 588 032 | Sell: 1 076 061 |
Forecast:
16:00 - $0.297
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.297
Forecast 2: 16:00 - $0.297
Forecast 3: 16:00 - $0.297
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.297 (-3.85% ) |
| Volume | 0.0176 mill |
| Avg. Vol. | 0.0673 mill |
| % of Avg. Vol | 26.15 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For QLGN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
QLGN
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-10 08:00:00 - Press Release
Qualigen Therapeutics' Novel Direct Pan-ras Inhibitors Presented At American Association Of Cancer Research (aacr) 2024 Annual Meeting
Poster includes preclinical data on novel direct pan-ras inhibitors carlsbad, calif., april 10, 2024 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or “the company,” nasdaq: qlgn) today announces a poster presentation on its preclinical novel direct pan-ras inhibitors was presented at the american association for cancer research (aacr) annual meeting 2024 held april 5 – 10 in san diego, california.
2024-04-09 08:00:00 - Press Release
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience With Qn-302, A Novel First-in-class G-quadruplex Experimental Anti-cancer Drug, At The American Association Of Cancer Research (aacr) 2024 Annual Meeting
Carlsbad, calif., april 09, 2024 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or the “company,” nasdaq: qlgn) today announces that a poster featuring its early clinical experience with a novel first-in-class g-quadruplex experimental anti-cancer drug, qn-302, was presented at the american association for cancer research (aacr) annual meeting 2024 held april 5 – 10 in san diego, california.
2023-11-14 16:30:00 - Press Release
Qualigen Therapeutics Provides Corporate Update For Third Quarter And To Date 2023
Carlsbad, calif., nov. 14, 2023 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, today provides a corporate update for the third quarter ending september 30, 2023 and to date:
2023-11-07 08:30:00 - Press Release
Qualigen Therapeutics Announces First Patient Dosed In The Phase 1a Clinical Trial Of Qn-302 For Treatment Of Advanced Or Metastatic Solid Tumors
Carlsbad, calif., nov. 07, 2023 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, announces today that the first patient in the phase 1a clinical trial has been dosed with qn-302, a potential first-in-class, investigational g-quadruplex (g4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors. the first clinical site is located at start midwest in grand rapids, michigan.
2023-10-23 08:30:00 - Press Release
Poster Highlighting Qualigen Therapeutics' Pan-ras Inhibitor Platform Presented At Aacr Special Conference: Advances In Breast Cancer
Poster includes preclinical data on pan-ras compounds demonstrating inhibition in breast cancer models
Latest News
2023-03-15 09:05:00 - GlobeNewsWire
Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023
CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the Company will be presenting five posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 to be held April 14-19 in Orlando, FL. The AACR Conference is a focal point of the cancer research community, where scientists, clinicians, other healthcare professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
2022-06-14 09:00:00 - GlobeNewsWire
Qualigen Therapeutics to Present at BIO International Convention
CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics will present a corporate overview at the BIO International Convention to be held on June 13 – 16, 2022 at the San Diego Convention Center.
2022-05-20 09:15:00 - GlobeNewsWire
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics Management will present a corporate overview during the H.C. Wainwright Global Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL and virtually.
2022-05-10 09:17:00 - GlobeNewsWire
Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed Israel
Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold
2022-04-12 15:02:47 - PennyStocks
Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today
Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-12 14:15:27 - InvestorPlace
Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?
Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket.
2022-04-12 11:24:01 - Benzinga
Qualigen Surges 80% As QN-302 Shows Potential Preclinical Mechanism Of Action Against Prostate, Pancreatic Cancers
Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are surging after highlighting posters at the American Association of Cancer Research (AACR). QN-302 showed potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo metastatic.
2021-12-28 16:37:38 - PennyStocks
Best Reddit Penny Stocks to Buy Now? 3 You Need to Watch in 2022
Check these three Reddit penny stocks out for your watchlist next year The post Best Reddit Penny Stocks to Buy Now? 3 You Need to Watch in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-12-27 09:28:14 - Benzinga
5 Short Squeeze Candidates To Watch: Biofrontera Rejoins And Tops List, 2 New Names Enter Leaderboard
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.
2021-12-26 16:30:00 - PennyStocks
Best Penny Stocks To Buy This Week? 3 For Your Watch List
Here are three penny stocks to watch right now The post Best Penny Stocks To Buy This Week? 3 For Your Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.